Compare Crispr Therapeutics AG (CRSP) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Uber Technologies Inc — how do they compare? Crispr Therapeutics AG trades at $50.91 (market cap $4.97B), while Uber Technologies Inc trades at $72.41 (market cap $146.73B). The key difference: Uber Technologies Inc is far larger — about 29.5× Crispr Therapeutics AG's market cap. Which is the better fit depends on your goals.
| CRSP | UBER | |
|---|---|---|
Market Cap | $4.97B | $146.73B |
Sector | Health | Industrials |
52-Week High | $76.78 | $100.10 |
52-Week Low | $44.34 | $68.61 |
Enterprise Value | $3.32B | $153.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Uber (UBER) trades at $72.08, down 3.3% over the past 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong revenue growth to $52.02B in 2025 and a net income of $10.05B, though Q4 2025 earnings missed expectations. Recent news highlights strategic moves into autonomous vehicles, including robotaxi pilots in Madrid and Munich, alongside cost-cutting measures such as HR layoffs and AI spending caps.
The outlook remains positive with an 81.67% analyst buy rating and a consensus price target of $108.92, suggesting significant upside. Key risks include execution challenges in autonomous driving, competitive pressures in key markets like India, and potential regulatory hurdles. Investors should weigh strong fundamentals against evolving industry dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
